次世代エネルギー産業・グリーン経済の国際リサーチ情報サイト

分子診断の世界市場:2025年市場予測と展望

THE MOLECULAR DIAGNOSTICS (MDX) MARKET FORECAST 2015-2025
Opportunities for Leading Companies

出版元:Visiongain(英国)出版元情報LinkIcon
発行年:2015年10月
定価 Single User License(1名様ライセンス) 1,799 GBP(英国ポンド) / Department License(5名様ライセンス) 2,999GBP/ Site License 4,999GBP / Global Site License 6,999GBP
ご請求は円換算(お見積り日TTSレート)となります。
納品形態:PDF by Email (※デジタル著作権管理/DRM設定有り)
当調査レポートは英文223ページになります。
商品コード:VGN474

お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。



【レポート紹介】
世界の分子診断市場は2019年段階で104億ドル規模に達し、以後2025年にかけて継続的な成長が見込まれます。世界的な人口高齢化や慢性疾患、とりわけ癌の有病率上昇などは分子診断の需要を下支えするでしょう。
当レポートでは、2025年に至る世界の分子診断の市場規模予測(US$)、診断分野別市場(感染症、がん、血液、遺伝子、組織適合性検査)、主要国別市場など、詳細にセグメントされた市場予測と分析を掲載しています。また当局規制、開発パイプライン、競合状況、リーディング企業7社動向などの調査解説も交えて、今後の市場機会と展望を明らかにしていきます。

【レポート構成概要】VGN474_PIC Molecular Diagnostics2025.jpg
◆分子診断(MDx)の世界市場予測2015-2025年(US$)

◆診断分野別、市場予測-2025と分析
・感染症検査
・がん検査
・血液検査
・遺伝子検査
・組織適合性検査(HLA)

◆主要国別、市場予測-2025と分析
・米国
・日本
・ドイツ
・フランス
・イタリア
・スペイン
・英国
・中国
・ブラジル
・ロシア
・インド
・韓国
・メキシコ

◆リーディング企業7社動向、製品分析、開発パイプライン、提携、今後展望等
・Roche Diagnostics
・Qiagen
・Hologic
・Becton, Dickinson & Company
・bioMérieux
・Cepheid
・Agilent Technologies

◆市場分析
・市場の多様性、各国の市場性理解の必要性
・不透明な当局規制の今後と対応を迫られる参入企業
・市場を再形成する潜在性を有する新興技術
・市場の促進要因と阻害要因、市場機会
・市場SWOT分析
・ポーターのファイブフォース分析(競合分析モデル)

◆調査結論
(全223ページ、145個のデータ表・グラフ類)

visiongain is a trading partner with the US Federal Government
【レポート詳細目次、データ項目一覧(List of Tables)は当ページ下を参照ください】

英文詳細目次(table of contents)

【原文詳細目次】

THE MOLECULAR DIAGNOSTICS (MDX) MARKET FORECAST 2015-2025
Opportunities for Leading Companies

Table of Contents

1. Report Overview

1.1 The Molecular Diagnostics Market Overview
1.2 Molecular Diagnostics Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About visiongain

2. Introduction to Molecular Diagnostics

2.1 What are In Vitro Diagnostic (IVD) Tests?
2.2 Classifying In Vitro Diagnostics
2.2.1 FDA Classifications
2.2.2 The EC (European Commission) Classification
2.2.3 IVD Classification in Australia
2.3 IVD Submarkets
2.3.1 Clinical Chemistry
2.3.2 Immunochemistry
2.3.3 Point-of-care Testing (Including Self-Monitoring Blood Glucose Tests)
2.3.4 Molecular Diagnostics
2.3.4.1 Infectious Disease Testing
2.3.4.2 Oncology Testing
2.3.4.3 Blood Screening
2.3.4.4 Genetic Testing
2.3.4.5 Tissue Typing (HLA Testing)
2.3.5 Clinical Microbiology
2.3.6 Haematology/ Haemostasis
2.4 Regulation of the IVD and MDx Market
2.4.1 FDA and CLIA Regulation of IVD and MDx Tests
2.4.2 Regulation of IVD/MDx Tests in the EU: The EC (European Commission) Classification
2.4.3 Top Ten Challenges in Regulation for In-Vitro Diagnostics
2.4.3.1 Challenges in Regulations of MDx Tests
2.5 Device Excise Tax: A Threat to the Diagnostics Manufacturers

3. The Molecular Diagnostics Segment within the In Vitro Diagnostics Market, 2015-2025

3.1 Molecular Diagnostics in the IVD Market, 2014
3.2 Sales Forecast for the Global IVD Market 2015-2025
3.3 Molecular Diagnostics Gaining A Greater Share of the IVD Market

4. The Molecular Diagnostics Market by Sectors, 2015-2025

4.1 The Molecular Diagnostic Market by Sectors, 2014
4.2 The Molecular Diagnostic Market by Sectors 2015-2025
4.2.1 Market Shares of the Molecular Diagnostics Sectors 2015-2025
4.3 The Infectious Disease Testing Market 2015-2025
4.3.1 Breakdown of the MDx Infectious Disease Testing Market by Disease, 2014
4.3.1.1 CT/NG
4.3.1.2 HPV Testing
4.3.1.3 HIV
4.3.1.4 Healthcare Associated Infections (HAI)
4.3.1.5 Hepatitis C (HCV)
4.3.1.6 Respiratory Infections
4.4 The Oncology Testing Market, 2015-2025
4.4.1 Targeted Therapies: A Major Driver of the Oncology Testing Market
4.4.2 Molecular Diagnostics: Currently Concentrated on a Few Cancer Indications
4.4.2.1 Breast Cancer
4.4.2.2 Prostate Cancer
4.4.2.2.1 Prostate Cancer Pipeline Biomarkers
4.4.2.2.1.1 TMPRSS2-ERG (OriGene)
4.4.2.2.1.2 PTEN
4.4.2.3 Colorectal Cancer
4.5 The Blood Screening Market 2015-2025
4.5.1 Grifols’ Acquisition of Novartis’s Blood Screening Unit
4.5.2 Leading Blood Screening Test Products
4.5.2.1 Cobas s 201 System (Roche Molecular)
4.5.2.2 Procleix Assays (Grifols)
4.6 The Genetic Testing Market 2015-2025
4.6.1 Genetic Testing by Clinical Impact Area
4.6.2 Genetic Testing: Potential beyond Oncology
4.6.3 Cystic Fibrosis
4.6.4 Factor V Leiden and Factor II Thrombophilia
4.6.5 Inflammatory Diseases
4.6.5.1 Alzheimer’s Disease (AD)
4.6.5.2 Rheumatoid Arthritis
4.6.5.2.1 Vectra®DA (Crescendo Bioscience)
4.6.5.2.2 Quest Diagnostics: Biomarker Study
4.6.5.3 Rare Diseases
4.7 The Tissue Typing (HLA Typing) Market 2015-2025
4.7.1 Tissue Typing: Next-Generation Sequencing

5. The Leading Molecular Diagnostics National Markets, 2015-2025

5.1 Regional Breakdown of the Global MDx Market, 2014
5.2 The Global MDx Market Forecast, 2015-2025
5.3 The Regional Market Shares of the MDx Market, 2014, 2019 and 2025
5.4 The US MDx Market 2014
5.4.1 The US MDx Market Forecast 2015-2025
5.4.1.1 United States: Diagnostic Reimbursement
5.5 The European MDx Markets Forecast 2015-2025
5.5.1 Changes in the Shares of the Leading European Markets, 2014, 2019 and 2025
5.5.2 Shares of the Major European Markets in a Global Context
5.5.3 The German MDx Market Forecast 2015-2025
5.5.3The French MDx Market Forecast 2015-2025
5.5.4 The Italian MDx Market Forecast 2015-2025
5.5.5 The Spanish MDx Market Forecast 2015-2025
5.5.6 The UK MDx Market Forecast 2015-2025
5.5.7 The Other European MDx Markets Forecast 2015-2025
5.6 The Japanese MDx Market Forecast 2015-2025
5.7 The Chinese MDx Market Forecast 2015-2025
5.7.1 China: Increasing Cancer Burden
5.8 The Brazilian MDx Market Forecast 2015-2025
5.9 The Russian MDx Market Forecast 2015-2025
5.10 The Indian MDx Market Forecast 2015-2025
5.10.1 India: Expansion of Healthcare Provisions
5.11 The South Korean MDx Market Forecast 2015-2025
5.12 The Mexican MDx Market Forecast 2015-2025
5.13 The Rest of the World Market Forecast 2015-2025

6. The Leading Companies in the Molecular Diagnostics Market, 2015

6.1 Roche Diagnostics
6.1.1 Roche: Global Presence
6.1.2 Roche Diagnostics, 2015-2025
6.1.3 Roche Diagnostics Business Performance within the IVD Market, 2014
6.1.3.1 Molecular Diagnostics Sales Performance, 2014
6.1.3.2 Molecular Diagnostic Sales by Region, 2014
6.1.4 Roche Diagnostics: MDx Product Launches and Indication Expansion, 2015
6.1.4.1 Roche Diagnostics: Product Launch Plans, 2015
6.1.5 Roche: Major M&A Activity and Strategic Partnerships Strengthen Position as Market Leader
6.1.5.1 Genia Acquisition to Strengthen DNA Sequencing Capabilities
6.1.5.2 IQuum Acquisition Allows Movement into POC MDx Market
6.1.5.3 Seragon Acquisition Strengthens Leading Position in Oncology
6.1.5.4 Santaris Acquisition Enchances Roche’s Position in RNA-Targeted Drugs Market
6.1.5.5 Bina Acquisition Brings Big Data Solution to Support NGS Development
6.1.5.6 Dutalys Acquisition Enhances Roche’s mAB Portfolio
6.1.5.7 Ariosa Acquisition Adds NIPT to MDx Portfolio
6.1.5.8 Foundation Medicine Deal Enhances Personalised Medicine Capabilities for Oncology
6.1.5.9 Signature and CAPP Acquisitions Strengthen Circulating DNA Testing Abilities
6.1.5.10 GENEWEAVE and Kapa Acquisitions Help Cement Roche’s Position as the MDx Market Leader
6.2 Qiagen NV
6.2.1 Sales and Recent Performance Analysis, 2014
6.2.2 Qiagen Sales by Region, 2014
6.2.3 Qiagen Sales by Segment, 2014
6.2.4 Qiagen: Molecular Diagnostics
6.2.5 Molecular Diagnostics: Product Expansion
6.2.5.1 QIASymphony
6.2.5.2 QuantiFERON-TB Gold: Expansion into Asia
6.2.5.3 Personalised Healthcare: Collaborative Efforts
6.2.5.4 Qiagen’s Software Company Acquisitions Cement Leadership in Bioinformatics
6.3 Hologic
6.3.1 Hologic Recent Sales Performance by Business Segment, 2014
6.3.2 Hologic Molecular Diagnostics: Product Portfolio
6.4 Becton, Dickinson and Company
6.4.1 Sales and Financial Performance, 2014
6.4.2 Sales and Financial Performance by Region, 2014
6.4.3 Becton, Dickinson and Company Diagnostics Sales and Financial Performance, 2013-2014
6.4.4 BD Diagnostics: Product Portfolio
6.4.5 BD Diagnostics: Mergers and Acquisitions
6.5 bioMérieux
6.5.1 Sales and Recent Performance Analysis, 2010-2014
6.5.2 Sales by Region, 2014
6.5.3 Sales by Technology, 2014
6.5.4 Molecular Diagnostics: Product Portfolio
6.5.5 Companion Diagnostics: Collaborations with GSK and Novartis
6.5.6 Mergers, Acquisitions and Collaborations
6.5.7 bioTheranostics: Subsidiary for Oncology Diagnostics
6.6 Cepheid
6.6.1 Sales and Recent Performance Analysis, 2010-2014
6.6.2 Sales by Industry Segment, 2013-2014
6.6.3 Sales by Region, 2012-2014
6.6.4 Cepheid: Product Line
6.6.5 Cepheid: Business strategy
6.7 Agilent Technologies
6.7.1 Sales and Recent Performance Analysis, 2014
6.7.2 Sales Performance by Business Segment, 2014
6.7.3 Agilent Technologies: Strong Player in Target Enrichment for Next-Generation Sequencing

7. Qualitative Analysis of the MDx Market, 2015-2025

7.1 MDx Market: Drivers and Restraints
7.2 SWOT Analysis of the MDx Market, 2015-2025
7.2.1 Strengths
7.2.1.1 Patient Demographics
7.2.1.2 Increased Awareness
7.2.1.3 High Growth in Oncology Molecular Diagnostics
7.2.1.4 Increasing Laboratory Test Menus
7.2.1.5 Personalised Medicine: Optimising Treatment Outcomes
7.2.2 Weaknesses
7.2.2.1 Lack of Clear Regulatory Guidelines for Molecular Diagnostics
7.2.2.2 Reimbursement Challenges for Molecular Diagnostic Companies
7.2.2.3 Consolidation of Healthcare Systems Increases Pricing Pressure
7.2.2.4 MDx: An Expensive, but Undervalued Diagnostic Tool
7.2.3 Opportunities
7.2.3.1 Next-Generation Sequencing
7.2.3.2 Emerging Markets
7.2.3.3 The Emergence of New Microorganisms
7.2.4 Threats
7.2.4.1 US Medical Device Excise Tax
7.2.4.2 Gene Patents: Controversial Ruling
7.3 Porter’s Five Forces Analysis of the MDx Market
7.3.1 Rivalry among Competitors [High]
7.3.2 Threat of New Entrants [Medium]
7.3.3 Power of Suppliers [Medium]
7.3.4 Power of Buyers [High]
7.3.5 Threat of Substitutes [High]

8. Research Interview

8.1 Kai te Kaat, Vice President, Global Product Management Life Sciences, Head of NGS Program, QIAGEN NV
8.1.1 QIAGEN: Pioneers in NGS Technology
8.1.2 The Future of NGS Outside Oncology
8.1.3 QIAGEN: Leading Progress in Bioinformatics
8.1.4 Regional Demand for NGS and NGS in the Wider Diagnostics Market

9. Conclusion

9.1 The Molecular Diagnostics Market: Growing Market Share
9.2 Molecular Diagnostics: Oncology Testing Market Growth
9.3 Commercial Drivers of the Molecular Diagnostics Market
9.4 Commercial Restraints of the Molecular Diagnostics Market
9.5 Emerging Markets
9.6 Concluding Remarks

10. Glossary

List of Tables

Table 1.1 Molecular Diagnostics Leading National Markets Forecast: Revenues ($bn), AGR (%) and CAGR (%), 2014-2025
Table 2.1 Advantages and Disadvantages of POC Diagnostics, 2015
Table 3.1 World IVD Market: Revenues ($bn) and Market Share (%) by Segment, 2014
Table 3.2 World IVD Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Segment, 2014-2025
Table 3.3 Market Shares (%) of MDx in the IVD Market, 2014, 2019 & 2025
Table 4.1 The MDx Market: Revenues ($bn) and Market Shares (%) by Segment, 2014
Table 4.2 The Global MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Segment, 2014-2025
Table 4.3 The MDx Market: Market Shares (%) by Segment, 2014, 2019 and 2025
Table 4.4 The Infectious Disease Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
Table 4.5 The Infectious Disease Testing Market: Revenues ($bn) and Market Share (%) by Disease, 2014
Table 4.6 Selected FDA and CE-Approved Molecular Diagnostics Test for CT/NG, 2015
Table 4.7 Selected FDA and CE-Approved Molecular Diagnostics Test for HPV, 2015
Table 4.8 Selected FDA and CE-Approved Molecular Diagnostics Tests for HIV, 2015
Table 4.9 Selected FDA and CE-Approved Molecular Diagnostics Test for HAIs, 2015
Table 4.10 Selected FDA and CE-Approved Molecular Diagnostics Tests for HCV, 2015
Table 4.11 Selected FDA-Approved Molecular Diagnostics Test for Respiratory Infections, 2015
Table 4.12 The Oncology Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
Table 4.13 Examples of Clinically Relevant Cancer Biomarkers Tied with a Drug, 2015
Table 4.14 Selected List of FDA-Approved MDx Tests for Breast Cancer, 2015
Table 4.15 Selected List of FDA-Approved MDx Tests for Prostate Cancer, 2015
Table 4.16 Selected List of FDA-Approved MDx tests for Colorectal Cancer, 2015
Table 4.17 The Blood Screening Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
Table 4.18 The Genetic Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
Table 4.19 Selected Genetic Tests for Cystic Fibrosis on the Market, 2015
Table 4.20 Selected Genetic Tests for Factor V Leiden/Factor II Thrombophilia on the Market, 2015
Table 4.21 Selected Alzheimer’s MDx Diagnostic Tests in Development, 2015
Table 4.22 The Tissue Typing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
Table 4.23 Selected tissue typing Kits on the Market, 2015
Table 5.1 The MDx Market: Revenue ($bn) and Market Share (%) by Region, 2014
Table 5.2 The MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Region, 2014-2025
Table 5.3 The MDx Market: Market Shares (%) by Regional Markets, 2014, 2019 and 2025
Table 5.4 The US MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
Table 5.5 The European MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
Table 5.6 The European MDx Market: Market Shares (%) by Country, 2014, 2019 and 2025
Table 5.7 The German MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
Table 5.8 The French MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
Table 5.9 The Italian MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
Table 5.10 The Spanish MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
Table 5.11 The UK MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
Table 5.12 The Other European MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
Table 5.13 The Japanese MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
Table 5.14 The Chinese MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
Table 5.15 The Brazilian MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
Table 5.16 The Russian MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
Table 5.17 The Indian MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
Table 5.18 The South Korean MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
Table 5.19 The Mexican MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
Table 5.20 The Rest of the World MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
Table 6.1 Roche Diagnostics: Revenue ($bn) and Revenue Share (%) by Business Area, 2014
Table 6.2 Roche Molecular Diagnostics: Revenue ($bn), Revenue Shares (%) by Region, 2014
Table 6.3 Roche Diagnostics: Key Product Launches (Instruments/Devices) Planned for 2015
Table 6.4 Roche Diagnostics: Key Product Launches (Tests/Assays) Planned for 2015
Table 6.5 Qiagen: Revenue ($m) and Revenue Share (%) by Region, 2012-2014
Table 6.6 Hologic: Revenue ($bn) and Revenue Share (%) by Segment, 2012-2014
Table 6.7 Hologic: Diagnostics Revenue ($bn) and Revenue Share (%) by Segment, 2014
Table 6.8 Becton, Dickinson and Company: Revenue ($bn) and AGR (%) by Region, 2012-2014
Table 6.9 Becton, Dickinson and Company: Sales ($bn), AGR (%) by Diagnostics Division, 2013-2014
Table 6.10 bioMérieux : Revenue ($bn) and AGR (%), 2010-2014
Table 6.11 bioMérieux: Revenue ($m) and Revenue Change (%) by Region, 2013-2014
Table 6.12 bioMérieux: Revenue ($bn) and Revenue Share (%) by Region, 2014
Table 6.13 bioMérieux: Revenue ($bn) and Revenue Change (%) by Technology, 2013-2014
Table 6.14 Cepheid: Revenue ($m) and Net Income ($m), 2010-2014
Table 6.15 Cepheid: Revenue ($m) and AGR (%) by Industry, 2012-2014
Table 6.16 Cepheid: Revenue ($m), AGR (%) and CAGR (%) by Region and Industry, 2012-2014
Table 6.17 Agilent Technologies: Revenue ($bn) and AGR (%), 2010-2014
Table 6.18 Agilent Technologies: Revenue ($bn) and AGR (%) by Business Segment, 2010-2014
Table 6.19 Agilent Technologies Life Sciences and Diagnostics: Revenue ($bn) by Segment, 2012-2014
Table 7.1 SWOT Analysis of the Global MDx Market, 2015-2025
Table 9.1 MDx and Other In Vitro Diagnostics: World Revenue ($bn) Forecast, 2014, 2019 and 2025

List of Figures

Figure 1.1 Molecular Diagnostics: Overview of Submarkets
Figure 3.1 World IVD Market: Revenues ($bn) by Segment, 2014
Figure 3.2 World IVD Market: Revenue Shares (%) by Segment, 2014
Figure 3.3 World IVD Market Forecast: Revenue ($bn) and AGR (%) by Segment, 2014-2025
Figure 3.4 World MDx Market Share (%) in the IVD Market, 2019
Figure 3.5 World MDx Market Share (%) in the IVD Market, 2025
Figure 4.1 The MDx Market Shares (%) by Sector in the IVD Market, 2014
Figure 4.2 The MDx Market: Revenue ($bn) by Segment, 2014
Figure 4.3 The MDx Market: Market Shares (%) by Segment, 2014
Figure 4.4 The Global MDx Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
Figure 4.5 The MDx Market: Market Shares (%) by Segment, 2019
Figure 4.6 The MDx Market: Market Shares (%) by Segment, 2025
Figure 4.7 The Infectious Disease Testing Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
Figure 4.8 The Infectious Disease Testing Market: Market Shares (%) by Disease, 2014
Figure 4.9 The Oncology Testing Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
Figure 4.10 The Cancer Treatment Sequence and the Application of Molecular Diagnostics and Companion Diagnostics
Figure 4.11 The Blood Screening Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
Figure 4.12 The Genetic Testing Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
Figure 4.13 The Genetic Testing Market by Clinical Impact Area, 2014
Figure 4.14 The Tissue Typing Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
Figure 5.1 The MDx Market: Market Shares (%) by Region, 2014
Figure 5.2 The MDx Market: Revenue ($bn) by Region, 2014
Figure 5.3 The MDx Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
Figure 5.4 The MDx Market: Market Shares (%) by Region, 2019
Figure 5.5 The MDx Market: Market Shares (%) by Region, 2025
Figure 5.6 The US MDx Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
Figure 5.7 The European MDx Market Forecast: Revenue ($bn) by Region, AGR (%), 2014-2025
Figure 5.8 The European MDx Market: Market Shares (%) by Country, 2014
Figure 5.9 The European MDx Market: Market Shares (%) by Country, 2019
Figure 5.10 The European MDx Market: Market Shares (%) by Country, 2025
Figure 5.11 Europe in The Global MDx Market: Market Shares (%) by Country, 2014
Figure 5.12 Europe in The Global MDx Market: Market Shares (%) by Country, 2019
Figure 5.13 Europe in The Global MDx Market: Market Shares (%) by Country, 2025
Figure 5.14 The German MDx Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
Figure 5.15 The French MDx Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
Figure 5.16 The Italian MDx Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
Figure 5.17 The Spanish MDx Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
Figure 5.18 The UK MDx Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
Figure 5.19 The Other European MDx Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
Figure 5.20 The Japanese MDx Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
Figure 5.21 The Chinese MDx Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
Figure 5.22 The Brazilian MDx Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
Figure 5.23 The Russian MDx Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
Figure 5.24 The Indian MDx Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
Figure 5.25 The South Korean MDx Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
Figure 5.26 The Mexican MDx Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
Figure 5.27 The Rest of the World MDx Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
Figure 6.1 Roche Diagnostics: Revenues ($bn) by Business Area, 2014
Figure 6.2 Roche Diagnostics: Revenue Share (%) by Business Area, 2014
Figure 6.3 Roche Molecular Diagnostics: Revenue Share (%) by Region, 2014
Figure 6.4 Qiagen:Revenue ($bn), Net Income ($bn) and Profit Margin (%), 2010-2014
Figure 6.5 Qiagen: Revenue ($m) by Region, 2014
Figure 6.6 Qiagen: Revenue Share (%) by Region, 2014
Figure 6.7 Hologic: Revenue ($bn) by Business Segment, 2012-2014
Figure 6.8 Hologic: Revenue Share (%) by Business Segment, 2014
Figure 6.9 Hologic: Diagnostics Revenue Share (%) by Business Segment, 2014
Figure 6.10 Becton, Dickinson and Company: Revenue Share (%) by Segment, 2014
Figure 6.11 Becton, Dickinson and Company: Revenue ($bn) by Region, 2012-2014
Figure 6.12 Becton, Dickinson and Company: Revenue Share (%) by Region, 2014
Figure 6.13 Becton, Dickinson and Company: Revenue Share (%) by Diagnostics Division, 2014
Figure 6.14 bioMérieux: Revenue ($m) and AGR (%), 2010-2014
Figure 6.15 bioMérieux: Revenue ($bn) by Region, 2014
Figure 6.16 bioMérieux: Revenue Share (%) by Region, 2014
Figure 6.17 bioMérieux: Revenue Share (%) by Technology, 2014
Figure 6.18 Cepheid: Revenue ($m) and Net Income ($m), 2010-2014
Figure 6.19 Cepheid: Revenue Share (%) by Industry, 2014
Figure 6.20 Cepheid: Revenue Share (%) by Region, 2012
Figure 6.21 Cepheid: Revenue Share (%) by Region, 2014
Figure 6.22 Agilent Technologies: Revenue ($bn) and AGR (%), 2010-2014
Figure 6.23 Agilent Technologies: Revenue Share (%) by Business Segment, 2014
Figure 6.24 Agilent Technologies Life Sciences and Diagnostics: Revenue Share (%) by Segment, 2014
Figure 7.1 MDx Market: Drivers and Restraints, 2015-2025
Figure 7.2 The Global Over 65 Population: Forecast (millions, AGR%), 2014-2025
Figure 7.3 Porter’s Five Forces Analysis of the MDx Market, 2015-2025
Figure 9.1 MDx and Other In Vitro Diagnostics: World Revenue ($bn) Forecast, 2014, 2019 and 2025
Figure 9.2 Molecular Diagnostics Market Forecast: AGRs (%) in the US, India, China and Global Market, 2014-2025

掲載企業リスト

Companies Listed

Abbott Laboratories / Abbott Molecular
AdvanDx
Agilent Technologies
Alere
ArcherDx
ARGENE
Ariosa Diagnostics
Atria Genetics
Astute Medical
Autogenomics, Inc.
AvariaDx
Becton, Dickinson & Co. / BD Diagnostics
Bina Technologies, Inc.
BIOBASE
Biocartis
BioFire Diagnostics
bioMérieux
Bio-Reference Laboratories
bioTheranostics
Boehringer Ingelheim
Bristo Myers Squibb
CAPP Medical
Celera Diagnostics
Cepheid
Chugai Pharmaceuticals
Clarient
CLC Bio.
Cognoptix
COPAN
Crescendo Bioscience
Dako A/S
Danaher Corporation
DiaGenic
DiagnoCure
Dutalys
DxS
EliTechGroup Epoch Biosciences
Enzymatics
Exact Sciences Corporation
Exosome
Focus Diagnostics, Inc.
Foundation Medicine
GE Healthcare
GenCell Biosystems
Genia Technologies, Inc.
Genentech
Genomic Health
GeneWEAVE Biosciences, Inc.
Gen-Probe
Gilead Sciences
Great Basin Scientific, Inc.
Grifols
Hain Lifescience
HandyLab
Hologic
IGEN International
Illumina, Inc.
Ingenuity Systems
Infectio Diagnstic, Inc.
Intelligent Medical Devices, Inc.
Ipsogen
IQuum, Inc.
IRIS International, Inc.
Janssen Diagnostics, LLC
Kapa Biosystems
Keysight Technologies Inc.
KIESTRA Lab Automation BV
Luminex Molecular Diagnostics, Inc.
MDx Health
Merck
Meridian Bioscience, Inc.
Meso Scale Diagnsotics
Myriad Genetic Laboratories, Inc.
Nanosphere, Inc.
Nanostring Technologies
Novartis
Olerup SSP AB
One Lambda
OPKO
OriGene
Ortho Clinical Diagnostics
Osmetech Molecular Diagnostics
PrimeraDx
Prodesse, Inc.
Proteome Sciences
Qiagen
Quest Diagnostics, Inc.
Quidel Corporation
RAS Lifesciences Pvt. Ltd
Roche Diagnostics (F. Hoffmann-La Roche Ltd.)
Saladax Biomedical Inc.
Santaris Pharma A/S
Seragon Pharmaceuticals, Inc.
Siemens Healthcare Diagnostics
Signature Diagnostics AG
Texas BioGene Inc.
Thermo Fisher Scientific
Ventana Medical Systems, Inc.
Veridex, LLC

Organisations Mentioned in the Report

American Medical Association
FDA’s Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)
French Court of Auditors
National Institute for Health and Clinical Excellence (NICE)
Rospotrebnadzor Federal Monitoring Agency
Rashtriya Swasthya Bima Yojana (RSBY) – (Indian National Health Insurance Programme)
Seguro Popular (Mexican National Health Insurance Programme)
United Nations Population Division
US Centers for Disease Control and Prevention (CDC)
US Centers for Medicare and Medicaid Services (CMS)
US Congressional Research Service (CRS)
US Food and Drug Administration (FDA)
USPS (United States Postal Service)
US National Healthcare Safety Network (NHSN)
World Health Organisation (WHO)

プレスリリース

プレスリリース

Memo.png当レポートのプレスリリースは発行されておりません。

2319881.jpg国内外のスマートグリッド関連ニュース、リサーチ情報等を収集し隔週でお届けいたします。日本そして海外の企業動向、新製品、政府支援、技術開発、規格、導入事例、投資、調査発表など幅広く情報を定期配信いたします。
スマートグリッド・ニュースへLinkIcon


ニュースページへLinkIcon

資料検索

お探しの資料・レポートをキーワードで検索ください。

当サイト内の検索結果が表示されます。調査レポートは英文目次を掲載しているため、英語検索も有効です。
(ブラウザのスクリプトを有効にしないとサーチエンジンが表示されません)

お問い合わせ

2714110_0.jpg
レポートをお探しいたします。
当サイトに掲載されているレポート以外にも幅広くご提案可能です。レポートの内容に関するご質問、ご確認にも回答いたします。お気軽にお問い合わせください。